In a further search for mechanism-based biomarkers, our present data provide evidence that sGPVI appears not to be suitable as a local stroke biomarker despite the fact that GPVI signaling is critically involved in the pathophysiology of AIS and has emerged as a novel therapeutic target currently under clinical testing [23]. Here, GP6 is linked to stroke disorder.